Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melanoma DNA vaccine - Oxxon Therapeutics

Drug Profile

Melanoma DNA vaccine - Oxxon Therapeutics

Alternative Names: Hi-8 MEL; MEL1 immunotherapy - Oxxon; pSG2.MEL3/MVA.MEL3

Latest Information Update: 15 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxxon Therapeutics
  • Developer Oxford BioMedica
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma in Germany and United Kingdom (unspecified route)
  • 05 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the Cancer therapeutic trials section
  • 16 May 2005 Phase-II clinical trials in Malignant melanoma in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top